Home Insights ISPOR Europe 2022

ISPOR Europe 2022

3 mins read

We’re excited to be attending and presenting at ISPOR Europe November 6—9th. This year’s conference theme is Collaborating Across Borders: Building & Using Evidence to Enable Access. Our HEOR and Market Access experts and colleagues across our Putnam PHMR team, including members of our team formerly known as Creativ-Ceutical, are looking forward to learning from other industry experts and sharing some of our own research and perspectives.

Here’s where you can find us:
  • Our HEOR and Market Access experts will be sharing posters in dedicated sessions throughout the conference, some in collaboration with clients. Look out for the following titles:

Economic burden and quality of life of caregivers of patients with sickle cell disease in the UK and France: A cross-sectional survey

A methodological study to compare alternative modes of administration for undertaking preference-elicitation studies

Distributional cost-effectiveness analysis of lung cancer treatments from an NHS England perspective

Cost-effectiveness analysis of the Oncotype DX® test to reduce under-treatment in patients with HR+/HER2-node negative early-stage breast cancer and Grade 2 T1C tumours

Cost-utility analysis of Avacopan for the treatment of Anca-Associated Vasculitis (AAV) patients in the UK

Utilisation of societal costs in the NICE HST approvals compared to European agencies

Assessing the content validity of preference-based measures in cancer

Public health impact and cost-effectiveness of empagliflozin (JARDIANCE®) in the treatment of patients with heart failure (HF) with preserved ejection fraction (HFpEF) in France, based on EMPEROR-Preserved clinical trial

Burden and characteristics of COVID-19 in France during 2020 based on national hospital database

A longitudinal study of epidemiology and treatment management of Wilson disease in France based on the French national claims database SNDS

The burden of Spinal Muscular Atrophy Type 2 (SMA2) on caregivers in Japan, United Kingdom, and United States: Results of a global survey

Public health impact and cost-effectiveness analysis of universal Varicella vaccination in the United Kingdom

Public health impact of COVID-19 in French ambulatory patients with at least one risk factor for severe disease

Public health impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Ecuador

Public health impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Dominican Republic

Cost-effectiveness of recombinant factor IX Fc prophylaxis and recombinant factor IX on-demand treatment in patients with haemophilia B without inhibitors

Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria

A systematic review of the burden of critical limb ischemia (CLI) among patients with peripheral arterial disease in Japan

Validating the clinical utility of intravascular ultrasound guidance during lower-extremity peripheral vascular interventions using claims data in Japan from 2009-2020: A real-world evidence study protocol

  • Podium Presentations:
    P2: The Value of Vaccination: Capturing the Impact of Vaccination on Health Equity in Health Economic Analysis
    Monday, November 7th 10:15-11:15 AM CET
    P33: Use of Real-World Evidence in European Medicines Agency Decisions
    Tuesday, November 8th 11:00-11:15 AM CET
  • Roche Symposium
    134: Inclusion of the Caregiver Perspective in Health Technology Assessment: The Case of Alzheimer’s Disease 
    Monday, November 7th 3-4 PM CET
  • BMS Issue Panel
    141: Not Another Value Framework Extension and Implementation of a Framework to Capture Holistic Value of New Medicines
    Monday, November 7th 4:30 – 5:30 PM CET

We hope to see you there. Please contact us with any questions and learn more about more program details here.

Contact us.